Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04187989
Other study ID # HUM00152202
Secondary ID R34DA045712
Status Completed
Phase N/A
First received
Last updated
Start date February 3, 2020
Est. completion date December 18, 2020

Study information

Verified date January 2022
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to develop and test social media interventions to help young people increase well-being and reduce risky behaviors. The study will help researchers learn about ways to deliver wellness information in a way that is appealing and helpful to young people who use Facebook.


Recruitment information / eligibility

Status Completed
Enrollment 149
Est. completion date December 18, 2020
Est. primary completion date December 18, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria: - self-report using cannabis at least 3 time per week or more often in the past month - active Facebook profile - view and click on a social media ad Exclusion Criteria: - fail identity verification based on 1) Internet Protocol (IP) addresses, 2) survey time completion, 3) repeat attempts, 4) survey responses, and 5) photo identification via a timestamped selfie sent to the research staff.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Social Media Intervention
Information will be posted by e-coaches. You can interact with the e-coaches as well as other study members in your group.

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of Cannabis Use as Reported on the Timeline Follow-Back (TLFB) 30-day TLFB self-report will be used to assess total number of days of cannabis use. 3-months post baseline
Primary Frequency of Cannabis Use as Reported on the Timeline Follow-Back (TLFB) 30-day TLFB self-report will be used to assess total number of days of cannabis use. 6-months post baseline
Primary Quantity of Cannabis Used as Reported on the Timeline Follow-Back (TLFB) 30-day Timeline Follow-Back (TLFB) self-report will be used to assess quantity (grams) of cannabis consumed. 3-months post baseline
Primary Quantity of Cannabis Used as Reported on the Timeline Follow-Back (TLFB) 30-day Timeline Follow-Back (TLFB) self-report will be used to assess quantity (grams) of cannabis consumed. 6-months post baseline
Primary Consequences of Cannabis Use as Measured by the Marijuana Adolescent Consequences Questionnaire Using Dichotomous Response Scale as Previously Described Throughout This Trial Registration. Marijuana Adolescent Consequences Questionnaire will be used to assess past 3 month consequences of cannabis use. Consequences are measured by report of number of times incidents from the list of 26 items (e.g., quality of work suffered, had less energy, etc.) resulted from cannabis use. Responses will be dichotomized (0 = never, 1= greater than never) and summed for a total score reflecting total number of consequences.
Response scale:
Never 1-2 times 3-5 times 6-10 times More than 10 times
Minimum score =0, maximum = 26. Higher score = more consequences.
3-months post-baseline
Primary Consequences of Cannabis Use as Measured by the Marijuana Adolescent Consequences Questionnaire Marijuana Adolescent Consequences Questionnaire will be used to assess past 3 month consequences of cannabis use. Consequences are measured by report of number of times incidents from the list of 26 items (e.g., quality of work suffered, had less energy, etc.) resulted from cannabis use. Responses will be dichotomized (0 = never, 1= greater than never) and summed for a total score reflecting total number of consequences.
Response scale:
Never 1-2 times 3-5 times 6-10 times More than 10 times
Minimum score =0, maximum = 26. Higher score = more consequences.
6-months post-baseline
Secondary Perceived Risk of Cannabis Use as Measured by 2 Modified Items From the Monitoring the Future Survey Two items rating current opinion on a scale from "no risk" to "great risk" of their perceived risk harm from occasional cannabis use and regular use.
Items are--
How much do you think people risk harming themselves (physically or in other ways), if they:
Use marijuana or marijuana products occasionally
Use marijuana or marijuana products regularly
Response options are:
No risk
Slight risk
Moderate risk
Great risk
Answers from both items are added together. The total range of two items summed can be 2-8. Higher totals indicate higher perceived risk.
3-months post-baseline
Secondary Perceived Risk of Cannabis Use as Measured by Modified Items From the Monitoring the Future Survey Two items rating current opinion on a scale from "no risk" to "great risk" of their perceived risk harm from occasional cannabis use and regular use.
Items are--
How much do you think people risk harming themselves (physically or in other ways), if they:
Use marijuana or marijuana products occasionally
Use marijuana or marijuana products regularly
Response options are:
No risk
Slight risk
Moderate risk
Great risk
Answers from both items are added together. The total range of two items summed can be 2-8. Higher totals indicate higher perceived risk.
6-months post-baseline
Secondary Peer Approval/Disapproval of Cannabis Use as Measured by Item Modified From Monitoring the Future Survey One item rating of current perception of whether their close friends would disapprove of their cannabis use (regardless of how much they use), rated as:
Not disapprove
Disapprove
Strongly disapprove
3 months post-baseline
Secondary Peer Approval/Disapproval of Cannabis Use as Measured by Item Modified From Monitoring the Future Survey One item rating of current perception of whether their close friends would disapprove of their cannabis use (regardless of how much they use), rated as: 1 Not disapprove 2 Disapprove 3 Strongly disapprove 6 months post-baseline
Secondary Cannabis Impaired Driving as Measured by 5 Items From the Modified Young Adult Driving Questionnaire Five items from the modified Young Adult Driving Questionnaire will be used to assess past 3 month driving under the influence of cannabis. Response values will be summed for a total score.
In the PAST 3 MONTHS...how many times did you drive within one hour after using marijuana or marijuana products containing THC?
how many times did you drive while a little high on marijuana or marijuana products containing THC?
how many times did you drive while very high on marijuana or marijuana products containing THC?
how many times did you drive when you knew your use of marijuana/marijuana products containing THC may already have affected your coordination?
how many times did you ride in a car or other vehicle driven by someone who had been using marijuana or marijuana products containing THC?
Response options:
0= Never
Once
Twice
3 times
4 times
5 times
6-9 times
10 or more times
3 months post-baseline
Secondary Cannabis Impaired Driving as Measured by 5 Items From the Modified Young Adult Driving Questionnaire Five items from the modified Young Adult Driving Questionnaire will be used to assess past 3 month driving under the influence of cannabis. Response values will be summed for a total score.
In the PAST 3 MONTHS...how many times did you drive within one hour after using marijuana or marijuana products containing THC?
how many times did you drive while a little high on marijuana or marijuana products containing THC?
how many times did you drive while very high on marijuana or marijuana products containing THC?
how many times did you drive when you knew your use of marijuana/marijuana products containing THC may already have affected your coordination?
how many times did you ride in a car or other vehicle driven by someone who had been using marijuana or marijuana products containing THC?
Response options:
0= Never
Once
Twice
3 times
4 times
5 times
6-9 times
10 or more times
6 months post-baseline
Secondary Other Drug Use as Measured by Items Modified From Monitoring the Future Survey Items from the Monitoring the Future Survey will be used to assess past 30 day use of 6 other substances - substances used and number of times of use. Response values will be summed for a total score using mid-point of the range scoring.
Substances assessed include: hallucinogens, opioids, stimulants, sedatives, lsd, ecstasy
Response scale:
0 0 Occasions
1-2 Occasions
3-5 Occasions
6-9 Occasions
10-19 Occasions
20-39 Occasions
40 or More Occasions
3 months post-baseline
Secondary Other Drug Use as Measured by Items Modified From Monitoring the Future Survey Items from the Monitoring the Future Survey will be used to assess past 30 day use of 6 other substances - substances used and number of times of use. Response values will be summed for a total score using mid-point of the range scoring.
Substances assessed include: hallucinogens, opioids, stimulants, sedatives, lsd, ecstasy
Response scale:
0 0 Occasions
1-2 Occasions
3-5 Occasions
6-9 Occasions
10-19 Occasions
20-39 Occasions
40 or More Occasions
6 months post-baseline
Secondary Frequency of Alcohol Consumption as Reported on the Timeline Follow-Back (TLFB) 30-day TLFB self-report will be used to assess total number of days of alcohol consumption. 3 months post-baseline
Secondary Frequency of Alcohol Consumption as Reported on the Timeline Follow-Back (TLFB) 30-day TLFB self-report will be used to assess total number of days of alcohol consumption. 6 months post-baseline
Secondary Quantity of Alcohol Consumption as Reported on the Timeline Follow-Back (TLFB) 30-day TLFB self-report will be used to assess the quantity of alcohol consumed. 3 months post-baseline
Secondary Quantity of Alcohol Consumption as Reported on the Timeline Follow-Back (TLFB) 30-day TLFB self-report will be used to assess the quantity of alcohol consumed. 6 months post-baseline
See also
  Status Clinical Trial Phase
Completed NCT03253926 - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Phase 1/Phase 2
Completed NCT04060602 - Personalized Feedback Intervention to Reduce Risky Cannabis Use. N/A
Completed NCT01212081 - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting NCT04988490 - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting NCT05188404 - Aging and Marijuana: Benefits, Effects, and Risks
Completed NCT03662737 - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting NCT04374773 - Effects of Pregnancy-associated Hormones on THC Metabolism in Women Phase 4
Completed NCT04316741 - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use N/A
Recruiting NCT05396638 - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder N/A
Recruiting NCT05309226 - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting NCT03859089 - Cannabis for Opioid Substitution Trial
Recruiting NCT05849636 - Alerta Cannabis: Evaluation of Web-based Tailored Intervention N/A
Enrolling by invitation NCT05521321 - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit N/A
Recruiting NCT05119244 - Environment and Lung Cancer N/A
Recruiting NCT04841655 - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated NCT04100590 - Eye Tracking as a Biomarker of Cannabis Effects Phase 2
Completed NCT05167097 - Mindsets and the Effectiveness of a Brief Intervention - Replication N/A
Recruiting NCT04114903 - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity